GO
Loading...

Gilead Sciences Inc

More

  • Midday Glance: Biotechnology companies Friday, 12 Dec 2014 | 1:18 PM ET

    Amgen Inc. rose$. 25 or. 1 percent, to $166.33. Biogen Idec rose $1.12 or. 3 percent, to $343.45. Celgene Corp. fell$. 99 or. 8 percent, to $115.75.

  • Early Glance: Biotechnology companies Friday, 12 Dec 2014 | 10:31 AM ET

    Amgen Inc. rose$. 24 or. 1 percent, to $166.32. Biogen Idec rose $3.18 or. 9 percent, to $345.51. Celgene Corp. fell$. 17 or. 1 percent, to $116.57.

  • Final Glance: Biotechnology companies Thursday, 11 Dec 2014 | 6:02 PM ET

    Amgen Inc. rose$. 69 or. 4 percent, to $166.08. Biogen Idec fell $1.26 or. 4 percent, to $342.33. Celgene Corp. rose $1.10 or 1.0 percent, to $116.74.

  • Midday Glance: Biotechnology companies Thursday, 11 Dec 2014 | 1:18 PM ET

    Amgen Inc. rose $2.69 or 1.6 percent, to $168.08. Biogen Idec rose $3.88 or 1.1 percent, to $347.47. Celgene Corp. rose $2.16 or 1.9 percent, to $117.80.

  • Early Glance: Biotechnology companies Thursday, 11 Dec 2014 | 11:28 AM ET

    Amgen Inc. rose $2.53 or 1.5 percent, to $167.92. Biogen Idec rose $2.90 or. 8 percent, to $346.49. Celgene Corp. rose $1.91 or 1.7 percent, to $117.55.

  • Final Glance: Biotechnology companies Wednesday, 10 Dec 2014 | 6:09 PM ET

    Amgen Inc. fell $4.00 or 2.4 percent, to $165.39. Biogen Idec fell $4.02 or 1.2 percent, to $343.59. Celgene Corp. fell $3.04 or 2.6 percent, to $115.64.

  • Gilead faces lawsuit over hepatitis C drug pricing Wednesday, 10 Dec 2014 | 5:59 PM ET

    HAVERFORD, Pa.— Philadelphia's Transportation Authority has filed a lawsuit against Gilead Sciences Inc. over the pricing of its hepatitis C drug. Gilead has been selling a 12- week treatment of Sovaldi in the United States for approximately $84,000, or $1,000 per pill. The Foster City, California, company could not be reached immediately for a comment...

  • Gilead sued over 'exorbitant' hepatitis C drug prices Wednesday, 10 Dec 2014 | 3:55 PM ET

    Dec 10- Philadelphia's transportation authority has filed a class action lawsuit accusing Gilead Sciences Inc of charging "exorbitant" prices for its blockbuster hepatitis C drug Sovaldi. The lawsuit, filed Tuesday in federal court in Philadelphia by the Southeastern Pennsylvania Transportation Authority, seeks an unspecified amount of money damages.

  • Midday Glance: Biotechnology companies Wednesday, 10 Dec 2014 | 1:18 PM ET

    Amgen Inc. fell $1.19 or. 7 percent, to $168.20. Biogen Idec fell $1.82 or. 5 percent, to $345.79. Celgene Corp. fell$. 97 or. 8 percent, to $117.71.

  • Early Glance: Biotechnology companies Wednesday, 10 Dec 2014 | 10:41 AM ET

    Amgen Inc. rose$. 07 or percent, to $169.46. Biogen Idec fell$. 17 or percent, to $347.44. Celgene Corp. fell$. 39 or. 3 percent, to $118.29.

  • Final Glance: Biotechnology companies Tuesday, 9 Dec 2014 | 6:10 PM ET

    Amgen Inc. fell $2.25 or 1.3 percent, to $169.39. Biogen Idec rose $3.56 or 1.0 percent, to $347.61. Celgene Corp. rose$. 49 or. 4 percent, to $118.68.

  • Midday Glance: Biotechnology companies Tuesday, 9 Dec 2014 | 1:21 PM ET

    Amgen Inc. fell $2.16 or 1.3 percent, to $169.48. Biogen Idec fell$. 23 or. 1 percent, to $343.82. Celgene Corp. rose$. 35 or. 3 percent, to $118.54.

  • Early Glance: Biotechnology companies Tuesday, 9 Dec 2014 | 10:21 AM ET

    Amgen Inc. fell $2.53 or 1.5 percent, to $169.11. Biogen Idec fell $2.51 or. 7 percent, to $341.54. Celgene Corp. fell $1.02 or. 9 percent, to $117.17.

  • Final Glance: Biotechnology companies Monday, 8 Dec 2014 | 6:02 PM ET

    Amgen Inc. rose $2.40 or 1.4 percent, to $171.64. Biogen Idec rose $3.18 or. 9 percent, to $344.05. Celgene Corp. rose $4.06 or 3.6 percent, to $118.19.

  • Midday Glance: Biotechnology companies Monday, 8 Dec 2014 | 1:20 PM ET

    Amgen Inc. rose $3.10 or 1.8 percent, to $172.34. Biogen Idec rose $3.09 or. 9 percent, to $343.96. Celgene Corp. rose $4.42 or 3.9 percent, to $118.55.

  • Early Glance: Biotechnology companies Monday, 8 Dec 2014 | 10:22 AM ET

    Amgen Inc. rose $2.22 or 1.3 percent, to $171.46. Biogen Idec rose $4.43 or 1.3 percent, to $345.30. Celgene Corp. rose $3.86 or 3.4 percent, to $117.99.

  • Lightning Round: Time to buy buy buy for 2015 Thursday, 4 Dec 2014 | 6:50 PM ET

    Are you ready skeedaddy???!!! It's time for the Lightning Round. Cramer makes the call on viewer favorites.

  • Cramer’s big discovery under the market's hood Wednesday, 3 Dec 2014 | 6:16 PM ET

    Jim Cramer takes a close look under the market's hood and makes a big discovery that could impact your portfolio.

  • Trader on the floor of the New York Stock Exchange.

    Some of Monday's midday movers:

  • Bristol-Myers said it had initially sought permission from the U.S. Food and Drug Administration to market the drug, a so-called NS5A inhibitor, in combination with asunaprevir, one of the New York- based company's experimental medicines. But Bristol-Myers abandoned its U.S. marketing application for asunaprevir in October because of potential...